PRIMUS-002: A Multicentre, Open-Label, Phase II Study Examining FOLFOX and Nab-Paclitaxel (FA) and Nab-Paclitaxel and Gemcitabine (AG) As Neoadjuvant Therapy for (borderline) Resectable Pancreatic Cancer (PC), Focusing on Biomarker and Liquid Biopsy Development.
Journal of Clinical Oncology（2024）
Key words
613-4678-146,261-3278,613-225-2575-3984,130-3426-5390-2622,298-145-222-184-1023-8966,613-135-2370-2813,261-566-9690,3618,219,1700,219,239,193,176,54
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined